ECSP045025A - Combinación de opioides seleccionados con antagonistas muscarnicos para el tratamiento de la incontinencia urinaria - Google Patents

Combinación de opioides seleccionados con antagonistas muscarnicos para el tratamiento de la incontinencia urinaria

Info

Publication number
ECSP045025A
ECSP045025A EC2004005025A ECSP045025A ECSP045025A EC SP045025 A ECSP045025 A EC SP045025A EC 2004005025 A EC2004005025 A EC 2004005025A EC SP045025 A ECSP045025 A EC SP045025A EC SP045025 A ECSP045025 A EC SP045025A
Authority
EC
Ecuador
Prior art keywords
treatment
urinary incontinence
combination
opioides
muscarnic
Prior art date
Application number
EC2004005025A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of ECSP045025A publication Critical patent/ECSP045025A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención está relacionada con el uso de una combinación de compuestos del grupo A, en particular opioides, y compuestos del grupo B, en particular agentes antimuscarínicos y otras sustancias que tienen una acción predominantemente periférica, para la preparación de un medicamento para el tratamiento del aumentos de la urgencia de orinar o de la incontinencia urinaria, y con los medicamentos y métodos correspondientes para el tratamiento del aumento de la urgencia de orinar o de la incontinencia urinaria.
EC2004005025A 2001-09-18 2004-03-17 Combinación de opioides seleccionados con antagonistas muscarnicos para el tratamiento de la incontinencia urinaria ECSP045025A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10146275A DE10146275A1 (de) 2001-09-18 2001-09-18 Kombination ausgewählter Opioide mit Muscarin-Antagonisten zur Therapie der Harninkontinenz

Publications (1)

Publication Number Publication Date
ECSP045025A true ECSP045025A (es) 2004-04-28

Family

ID=7699618

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005025A ECSP045025A (es) 2001-09-18 2004-03-17 Combinación de opioides seleccionados con antagonistas muscarnicos para el tratamiento de la incontinencia urinaria

Country Status (21)

Country Link
US (2) US20040242617A1 (es)
EP (1) EP1429754B1 (es)
JP (1) JP4511176B2 (es)
KR (1) KR100891438B1 (es)
CN (1) CN100384413C (es)
AT (1) ATE383854T1 (es)
AU (1) AU2002342707B2 (es)
BR (1) BR0212714A (es)
CA (1) CA2460655C (es)
DE (2) DE10146275A1 (es)
EC (1) ECSP045025A (es)
ES (1) ES2299608T3 (es)
HU (1) HUP0401485A3 (es)
IL (2) IL160894A0 (es)
MX (1) MXPA04002510A (es)
NO (1) NO333016B1 (es)
NZ (1) NZ531777A (es)
PL (1) PL209272B1 (es)
RU (1) RU2305562C2 (es)
WO (1) WO2003024444A1 (es)
ZA (1) ZA200402853B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10146275A1 (de) 2001-09-18 2003-04-24 Gruenenthal Gmbh Kombination ausgewählter Opioide mit Muscarin-Antagonisten zur Therapie der Harninkontinenz
US7410965B2 (en) 2002-05-29 2008-08-12 Gruenenthal Gmbh Delayed release pharmaceutical composition containing 1-dimethyl-amino-3-(3-methoxyphenyl)-2-methyl-pentan-3-ol
DE10224108A1 (de) * 2002-05-29 2004-01-29 Grünenthal GmbH 1-Dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol enthaltendes Arzneimiitel mit verzögerter Wirkstofffreisetzung
DE10224556A1 (de) * 2002-05-31 2004-01-08 Grünenthal GmbH 1-Dimethylamino- 3-(3-methoxy-phenyl)2-methyl-pentan-3-ol entaltendes Arzneimittel in verschiedenen Formulierungen
ES2288641T3 (es) * 2002-12-20 2008-01-16 Dynogen Pharmaceuticals Inc. Metodo para tratar trastornos indoloros de la vejiga usando moduladores de canales del calcio de la subunidad alfa2-delta.
EP1721607A1 (en) * 2003-03-21 2006-11-15 Dynogen Pharmaceuticals, Inc. Methods for treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators
DE10356362A1 (de) * 2003-11-28 2005-06-23 Grünenthal GmbH Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie von Angststörungen
BRPI0511137A (pt) * 2004-05-14 2007-11-27 Janssen Pharmaceutica Nv compostos opióides de carboxamido
DE102005009217A1 (de) * 2005-02-25 2006-08-31 Grünenthal GmbH Phosphatsalze der 6-Dimethylaminomethyl-1-(3-methoxyphenyl)-1,3-dihydroxy-cyclohexanverbindungen
EP1907351A1 (de) * 2005-07-22 2008-04-09 Grünenthal GmbH Hcl-polymorphe von 3 - ( 2- (dimethylamino) methyl- ( cyclohex-i-yl) ) phenol
US7884247B2 (en) * 2005-07-22 2011-02-08 Gruenenthal Gmbh Salt of dimethylaminomethyl-phenyl-cyclohexane and crystalline forms thereof
US20070032551A1 (en) * 2005-07-22 2007-02-08 Gruenenthal Gmbh Salt of dimethylaminomethyl-phenyl-cyclohexane and crystalline forms thereof
DE102007022790A1 (de) * 2007-05-11 2008-11-20 Grünenthal GmbH Axomadol zur Schmerzbehandlung bei Arthrose
NZ592437A (en) * 2008-10-30 2013-03-28 Gruenenthal Chemie A dosage form comprising tapentadol and an opioid antagonist
EP2545027A1 (de) 2010-03-10 2013-01-16 Grünenthal GmbH Kristalline salze und/oder cokristalle von o-desmethyltramadol
BR112012028773A2 (pt) 2010-05-10 2016-07-19 Euro Celtique Sa composições farmacêuticas compreendendo hidromorfona e naloxona
CA2798885C (en) 2010-05-10 2014-11-18 Euro-Celtique S.A. Combination of active loaded granules with additional actives
AU2011252040C1 (en) 2010-05-10 2015-04-02 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
CN103040828B (zh) * 2013-01-07 2015-12-02 常州康普药业有限公司 复方地芬诺酯片及其制备方法
EP3068397A1 (en) 2013-11-13 2016-09-21 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB857194A (en) * 1957-07-05 1960-12-29 Clinical Products Ltd Therapeutic agents comprising ion-exchange resins
NL127065C (es) 1964-04-22
US5736577A (en) 1995-01-31 1998-04-07 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
DE3012837A1 (de) * 1979-04-10 1980-10-30 Sandoz Ag Analgetische und myotonolytische praeparate
DE3129982A1 (de) * 1981-07-29 1983-02-17 Jutta 8200 Rosenheim Meyer "antiallergikum"
US5073560A (en) 1990-07-20 1991-12-17 Fisons Corporation Spiro-isoxazolidine derivatives as cholinergic agents
DE4041559A1 (de) 1990-12-22 1992-06-25 Boehringer Ingelheim Kg Neue wirkstoffkombinationen
SE9202218D0 (sv) * 1992-07-22 1992-07-22 Kabi Pharmacia Ab Pharmacologically active alfa-(tertiary-aminomethyl)-benzenemethanol derivatives, pharmaceutical composition containing them, therapeutical use thereof and processes for their preparation
ATE195733T1 (de) * 1993-07-30 2000-09-15 Delta Pharmaceuticals Inc Als heilmittel nutzbare piperazin verbindungen
DE4426245A1 (de) * 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
ES2214532T3 (es) * 1995-03-03 2004-09-16 Endo Pharmaceuticals Inc. Uso de dextrorfano o dextrometorfano para el tratamiento de la incontinencia urinaria.
DE19525137C2 (de) 1995-07-11 2003-02-27 Gruenenthal Gmbh 6-Dimethylaminomethyl-1-phenyl-cyclohexanverbin -dungen als Zwischenprodukte zur Herstellung pharmazeutischer Wirkstoffe
DE19609847A1 (de) * 1996-03-13 1997-09-18 Gruenenthal Gmbh Dimethyl-(3-aryl-but-3-enyl)-aminverbindungen als pharmazeutische Wirkstoffe
JP2000515525A (ja) 1996-07-19 2000-11-21 アベーグ，グンナー 尿と胃腸の疾患の治療におけるｓ（―）―トルテロジン
AU6747698A (en) * 1997-04-11 1998-11-11 Nippon Shinyaku Co. Ltd. Remedies for frequent urination and urinary incontinence
PE20010623A1 (es) * 1999-10-05 2001-07-07 Gruenenthal Chemie Uso de (+)-tramadol y/o o-demetiltramadol para tratamiento de urgencia urinaria incrementada y/o incontinencia urinaria
CN1660435A (zh) * 2000-02-24 2005-08-31 法玛西雅厄普约翰美国公司 新的药物联合形式
DE10059412A1 (de) * 2000-11-30 2002-06-13 Gruenenthal Gmbh Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie der Harninkontinenz
DE10146275A1 (de) 2001-09-18 2003-04-24 Gruenenthal Gmbh Kombination ausgewählter Opioide mit Muscarin-Antagonisten zur Therapie der Harninkontinenz

Also Published As

Publication number Publication date
MXPA04002510A (es) 2004-05-31
NO333016B1 (no) 2013-02-18
HUP0401485A2 (hu) 2004-11-29
JP4511176B2 (ja) 2010-07-28
DE50211566D1 (de) 2008-03-06
EP1429754B1 (de) 2008-01-16
RU2004111788A (ru) 2005-06-10
RU2305562C2 (ru) 2007-09-10
US8946290B2 (en) 2015-02-03
US20120016023A1 (en) 2012-01-19
KR20040044953A (ko) 2004-05-31
BR0212714A (pt) 2004-08-03
KR100891438B1 (ko) 2009-04-03
NZ531777A (en) 2006-11-30
EP1429754A1 (de) 2004-06-23
PL369235A1 (en) 2005-04-18
ZA200402853B (en) 2005-02-23
HK1075205A1 (zh) 2005-12-09
DE10146275A1 (de) 2003-04-24
JP2005507387A (ja) 2005-03-17
AU2002342707B2 (en) 2006-10-12
WO2003024444A1 (de) 2003-03-27
PL209272B1 (pl) 2011-08-31
US20040242617A1 (en) 2004-12-02
IL160894A0 (en) 2004-08-31
CA2460655C (en) 2012-02-07
ES2299608T3 (es) 2008-06-01
ATE383854T1 (de) 2008-02-15
CA2460655A1 (en) 2003-03-27
CN1589140A (zh) 2005-03-02
IL160894A (en) 2010-04-29
CN100384413C (zh) 2008-04-30
NO20041059L (no) 2004-05-12
HUP0401485A3 (en) 2008-04-28

Similar Documents

Publication Publication Date Title
ECSP045025A (es) Combinación de opioides seleccionados con antagonistas muscarnicos para el tratamiento de la incontinencia urinaria
AR045179A1 (es) Uso de una combinacion de un inhibidor de la quinasa del receptor del factor de crecimiento epidermico y de agentes citotoxicos para el tratamiento e inhibicion del cancer
AR028959A1 (es) Uso de rapamicina para la manufactura de un medicamento para tratar enfermedades cardiovasculares
ECSP003847A (es) Composiciones farmaceuticas que proporcionan concentraciones potenciadas de farmaco
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
AR027968A1 (es) Una composicion para utilizar en el tratamiento y/o prevencion del sarampion y el uso de dicha composicion para un vehiculo para el tratamiento o prevencion del sarampion
BR0112311A (pt) Compostos e composições para liberar agentes ativos, forma de dosagem unitária, método para preparar ditas composições e seu uso
ECSP055840A (es) Derivados de 4 -tetrazolil-4fenilpiperidina para el tratamiento del dolor
NO20031672D0 (no) Aza- og polyaza-naftalenylkarboksamider for anvendelse som HIV-integraseinhibitorer
AR048878A1 (es) Composiciones topicas de metadona y metodos para usarlas
CL2007001724A1 (es) Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
AR044039A1 (es) Combinaciones antineoplasicas
DE69932510D1 (de) Vaskularisierungsinhibitoren
AR034900A1 (es) Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica
ES2190205T3 (es) Combinacion para el tratamiento de la dependencia del alcohol que contiene un antagonista opioide y un modulador del complejo receptor de nmda.
AR047988A1 (es) Combinaciones antineoplásicas de cci-779 y rituximab
CL2008003938A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00).
AR034517A1 (es) Formulacion farmaceutica
PE20010623A1 (es) Uso de (+)-tramadol y/o o-demetiltramadol para tratamiento de urgencia urinaria incrementada y/o incontinencia urinaria
ATE286397T1 (de) Wirkstoff-kombination (z.b. galanthamin oder desoxypeganin mit acamprosat oder memantin) zur medikamentösen sucht- oder rauschmitteltherapie
SI1276476T1 (sl) Uporaba bradikardnih snovi pri zdravljenju miokardnih bolezni, povezanih s hipertrofijo, in nove kombinacije zdravil
AR041713A1 (es) Una composicoin farmaceutica de duracion prolongada
NO20035602D0 (no) Sammensetning som omfatter en PDE-4-inhibitor og H1- reseptorantagonist, samt anvendelse derav til fremstilling av et medikament forbehandling av åndedrettsykdommer
BR0114814A (pt) Composições compreendendo composto de modafinila e seu uso
AR028502A1 (es) Tratamiento de condiciones inflamatorias alérgicas